Clinical Studies Published in the Top Dermatology Journals
Is the Lumixyl Peptide Technology Backed By Solid Clinical Studies?
This is a great question to ask about any skin care product that claims to brighten skin. The answer for Lumixyl is absolutely yes! This product is one of the most exciting breakthroughs in skin brightening to come along in the last 50 years precisely because it was developed through the clinical studies and development efforts of a team of Stanford Dermatologists. Several journal publications have documented the clinical results of Lumixyl in recent months.
One of several study publications can be found in the August ?09 Journal of Drugs in Dermatology.
A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.
Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl) was previously shown to competitively inhibit mushroom and human tyrosinase without the associated toxicity of hydroquinone. The aim of this split-face, randomized, double-blind and placebo-controlled pilot study was to determine the effect of twice-daily topical application of this oligopeptide (0.01% w/w) on moderate, recalcitrant melasma over a 16-week course. Five female participants with Fitzpatrick phototype IV and moderate recalcitrant melasma enrolled and completed the study. Improvement in melasma and overall facial aesthetics as well as assessment of volunteer satisfaction was measured using 10- and five-point grading scales, respectively. Treatment was well tolerated with no visible signs of irritation or allergy. All five participants demonstrated statistically significant improvement in the appearance of melasma and overall facial aesthetics with high patient satisfaction. Results suggest that the oligopeptide may be useful in the treatment of melasma and warrants further evaluation.
Another study published in the Journal of Investigative Dermatology documents the powerful mechanism of action that the peptides have in inhibiting tyrosinase (a key enzyme your skin uses to create melanin). It is also a startling illustration of the cytotoxic nature of hydroquinone (it?s tendency to cause cell death as exposure to healthy tissue is increased), versus the virtually non-toxic nature of the Lumixyl Peptide ? as follows;
Short-Sequence Oligopeptides with Inhibitory Activity against Mushroom and Human Tyrosinase
Cutaneous hyperpigmentation is a common disorder due to excess melanin production by the enzyme tyrosinase. The gold standard for treatment is hydroquinone (HQ), which reduces pigmentation through its toxicity to melanocytes rather than via tyrosinase inhibition. We screened an internal library for oligopeptides that inhibited both mushroom and human tyrosinase but showed no cytotoxicity to human melanocytes. We identified two highly active inhibitory sequences, P3 and P4, of 8- and 10-amino-acid-length, respectively. Mushroom tyrosinase inhibition was dose-dependent with IC50 (half-maximal inhibitory concentration) values of 123 and 40 μM, respectively, compared with 680 μM for HQ. Other oligopeptides showed weaker or no inhibitory activity. Kinetic studies showed that P3 and P4 are competitive inhibitors of mushroom tyrosinase. At 100 μM, P3 and P4 inhibited human tyrosinase by 25?35%. This inhibition partially depended on whether L-dopa or L-tyrosine was the substrate, suggesting that tyrosinase may contain contains two distinct catalytic sites. Treatment of melanocytes with 100 μM P3 or P4 for 7 days led to a 27 or 43% reduction in melanin content. This inhibition was independent of cell proliferation and cytotoxic effects. Our data suggest that peptide-mediated inhibition of melanogenesis is due to reduction in tyrosinase activity.
Keep in mind ? these are not flimsy ?Marketing? studies. The JDD study for example uses state of the art clinical study structure. Let me break it down by explaining the study heading line-by-line;
- A split-face ? the same patients were treated with the Lumixyl peptide on one side of their face, and a ?placebo? creme on the other. This makes the patient selection completely objective and equal.
- double-blind ? a blind study is where the patient does not know which side is Lumixyl and which is not. A double blind study means that even the people administering the test do not know ? so that they remain completely objective about what they are seeing in the results.
- randomized ? Pictures and data of the patients are taken and then supplied to experts not involved in collecting the data in random order so that they have no idea which results belong to Lumixyl and which do not.
- placebo-controlled ? As noted above, this is not just a matter of whether the Lumixyl peptide improves the skin, but whether it significantly improves the skin versus a placebo ?control?.
All together, this is the highest standard of dermatologic clinical study structure, and the results are exciting, as every patient involved experienced a significant improvement in 8 weeks of Lumixyl peptide treatment, versus the placebo. One more fact that make this all the more amazing ? the study was conducted on patients with recalcitrant melasma. That is, in order to be in the study, the patient had to have failed to see success when treated previously with a hydroquinone/retinoid therapy. And yet each of them experienced significant improvement in this study.
This, and the amazing results that patients are now seeing every day around the world, is why we can confidently say that the future of skin care just got a lot brighter.